

Review article

R.J. REITER¹, S. ROSALES-CORRAL¹, A. COTO-MONTES¹, J.A. BOGA¹, D.-X. TAN¹,
J.M. DAVIS², P.C. KONTUREK², S.J. KONTUREK³, T. BRZOZOWSKI³

THE PHOTOPERIOD, CIRCADIAN REGULATION AND CHRONODISRUPTION: THE REQUISITE INTERPLAY BETWEEN THE SUPRACHIASMATIC NUCLEI AND THE PINEAL AND GUT MELATONIN

¹Department of Cellular and Structural Biology, UT Health Science Center San Antonio, Texas, USA; ²Department of Internal Medicine, Thuringia, Saalfeld, Germany; ³Department of Physiology, Jagiellonian University Medical College, Cracow, Poland

The current scientific literature is replete with investigations providing information on the molecular mechanisms governing the regulation of circadian rhythms by neurons in the suprachiasmatic nucleus (SCN), the master circadian generator. Virtually every function in an organism changes in a highly regular manner during every 24-hour period. These rhythms are believed to be a consequence of the SCN, *via* neural and humoral means, regulating the intrinsic clocks that perhaps all cells in organisms possess. These rhythms optimize the functions of cells and thereby prevent or lower the incidence of pathologies. Since these cyclic events are essential for improved cellular physiology, it is imperative that the SCN provide the peripheral cellular oscillators with the appropriate time cues. Inasmuch as the 24-hour light:dark cycle is a primary input to the central circadian clock, it is obvious that disturbances in the photoperiodic environment, *e.g.*, light exposure at night, would cause disruption in the function of the SCN which would then pass this inappropriate information to cells in the periphery. One circadian rhythm that transfers time of day information to the organism is the melatonin cycle which is always at low levels in the blood during the day and at high levels during darkness. With light exposure at night the amount of melatonin produced is compromised and this important rhythm is disturbed. Another important source of melatonin is the gastrointestinal tract (GIT) that also influences the circulating melatonin is the generation of this hormone by the entero-endocrine (EE) cells in the gut following ingestion of tryptophan-containing meal. The consequences of the altered melatonin cycle with the chronodisruption as well as the alterations of GIT melatonin that have been linked to a variety of pathologies, including those of the gastrointestinal tract.

Key words: *biological clock, chronodisruption, circadian rhythm, gastrointestinal melatonin, peptic ulcer, pineal gland, suprachiasmatic nucleus*

INTRODUCTION

Biological rhythms are essential for optimal health (1, 2). Throughout the course of human evolution, hominids were exposed to regularly alternating periods of light and dark during every 24-hour period. This evolutionary period, which for humans may have lasted for three million or more years, allowed species to take advantage of the light:dark cycle to adjust their physiology and to synchronize it with the prevailing light:dark environment. To take advantage of this information, vertebrates, including hominids, evolved a group of neurons to monitor the photoperiodic environment and to adjust organismal, organ and cellular function accordingly.

This paired group of light-responsive neurons is located in the mediobasal preoptic area at the diencephalic-telencephalic junction just anterior to the hypothalamus. Since these neurons lie immediately above the decussating axons of the optic nerve, *i.e.*, the optic chiasma, they are named the suprachiasmatic nuclei (SCN) (3, 4). The SCN orchestrate all known circadian

rhythms in vertebrates and are referred to as the master biological clock or the central rhythm generator.

THE SUPRACHIASMATIC NUCLEUS

The paired set of neurons that constitute the SCN exhibits an intrinsic cycle of electrical activity that is not precisely 24 hours in duration (*Fig. 1*). Rather the period of this rhythm is, in fact, closer to 25 hours (5). Thus, the neural "clock" runs slow. If this rhythm would not be adjusted nearer to a 24-hour cycle, the physiology of the organism would quickly be out of phase with the appropriate environmental time, *i.e.*, the organism would be desynchronized or chronodisrupted (6-8). This assertion is supported by studies of completely blind people, who naturally develop desynchronized - 'free-running' - biological rhythms, which can be entrained by administration of exogenous melatonin (9, 10). This is reminiscent of an individual being in the state of "jet lag." Moreover, this would compromise

The induction of nocturnal pineal melatonin synthesis is accompanied by a rapid discharge of the indoleamine from the pinealocytes into the capillaries that perfuse the gland as well as into the cerebrospinal fluid of the third ventricle of the brain. As a consequence, as pineal melatonin production increases likewise the levels of this indoleamine rise in these fluids (45-47). Thus, the circadian rhythm of melatonin is inextricably linked to the prevailing light: dark environment. Interruption of the neural pathway bilaterally at any point between the SCN and the pineal gland destroys the circadian melatonin rhythm and renders the pineal gland physiologically inept (48).

As mentioned above, light pulses during darkness cause misinformation to be sent to the SCN; in turn, the clock neurons pass this information to the pinealocytes *via* the complex pathway described above, and pineal melatonin synthesis and secretion cease (49). This results in a rapid drop in circulating melatonin levels at a time they should be elevated. As a result, this disturbance of the circadian melatonin cycle is provided to all cells in the periphery giving these cells the wrong time of day information and contributing to chronodisruption and pathophysiology (51-54).

It is only after the invention of the artificial light that the regularly alternating periods of light and darkness could be seriously disturbed. The common use of artificial light after darkness onset, a situation that is especially prominent in the well-developed countries but that is also becoming usual in virtually all societies, provides the circadian system with a great deal of misinformation to which it responds.

In reference to the nocturnal rise in melatonin, light during the normal dark period has two major consequences. When the daily light period is extended into the night or when the period of darkness is prematurely terminated by early light exposure in the morning, the nocturnal period of melatonin production is abbreviated. Likewise, if during the night individuals are acutely exposed to light, these photons signal the ipRGCs to shut down pineal melatonin production. In both of these scenarios, *i.e.*, extension of light into the dark period or acute light exposure at night, the circadian system is upset and melatonin production and secretion is compromised. As a consequence, what is referred to as the misuse of light has rendered humans relatively melatonin deficient (when light is extended into the night) or it causes the perturbed melatonin rhythm (when light occurs acutely at night) to provide incorrect circadian information to all cells capable of "reading" the melatonin message, and many (possibly all) cells do.

CONSEQUENCES OF DISTURBING THE MELATONIN RHYTHM AND ALTERING THE CIRCADIAN SYSTEM

As noted above, the artificial extension of the daily light period into the night with the use of manufactured light or, conversely, being exposed to light in the early morning before sunrise, shortens the dark interval and thereby reduces the total amount of melatonin produced without actually changing its rhythm (55), *i.e.*, low blood levels during the day and elevated values at night. Thus, the circadian message that the melatonin rhythm imparts to the cells throughout the organism under these conditions is not lost. Nevertheless, there is a reduction in the total amount of melatonin generated (a relative melatonin deficiency) during each 24-hour interval, at least based on blood melatonin levels. In this case, chronodisruption is presumably not a consideration but the reduced amount of melatonin likely is.

Even independent of the relative melatonin deficiency that occurs when the night is shortened is the abbreviated duration of sleep. Ample sleep is an important feature of optimal physiology during the waking hours (56). In the US, the duration of sleep (and the associated period of daily dark exposure) has decreased steadily

over the last five decades from roughly 8 hours in the 1960s to 6.5 hours in the early 21st century (57, 58). The resulting sleepiness that is a consequence of the sleep debt these individuals experience is estimated to have a significant negative impact on work efficiency and productivity and, as a result, the cost to industry is surely in the range of millions of dollars annually. Additionally, the health effects of inadequate sleep are also a major concern. It seems intuitive that the failure to get adequate sleep, especially when extended over time, may well lead to altered physiology and compromised health which, of course, impacts life quality (59).

In addition to any pathophysiology that may develop as a result of reduced daily sleep intervals is the associated deficiency of melatonin that occurs as a consequence of extended daily light periods. Given the multiple functions of melatonin (60, 61) and the fact that it and its metabolites fight against free radicals and the molecular damage that they mete out (62-65), the reduction in melatonin associated with artificially-induced long days would surely enhance the degree of oxidative damage that cells incur (66). Conquering free radicals, which are produced as a consequence of normal cellular metabolism especially at the mitochondrial level, is essential for maintaining good health (63, 67).

Melatonin is a multifaceted antioxidant which, even at physiological levels, engages free radicals and related toxic species, *i.e.*, reactive oxygen and reactive nitrogen intermediates, to detoxify them before they inflict damage. By reducing the length of the daily dark period and consequently simultaneously limiting the amount of pineal melatonin produced on a daily basis is, in a sense, reminiscent of what also occurs in advanced age. As organisms grow old, endogenous melatonin production wanes judging from the reduced nocturnal melatonin rise (68-70). The loss of this protective molecule allows free radicals, which are believed to be produced at an increasingly more rapid rate in aged and less optimally functioning cells (71), to go unchallenged thereby elevating the damage they are capable of inflicting. Certainly, supplementing aged animals with extra melatonin readily reduces the accumulated free radical-damaged cellular debris (72-74). Predictably, this would also curtail the development of disease states. The parallels between aging and prematurely reducing total melatonin production by excessive light exposure would be expected to cause similarly elevated free radical-mediated cellular damage. One implication of this is that disease processes related to oxidative stress which normally are most common in advanced age may in fact develop earlier in life. Experimentally, giving animals extra melatonin after middle age has been shown to defer the development or severity of age-related diseases (72, 75).

Interrupting the dark period with acute light exposure not only rapidly reduces pineal melatonin synthesis as well as lowering its levels in the blood, this abnormal light exposure also leads to severe chronodisruption (6). When nighttime melatonin levels are high, exposure of humans or animals to bright and wave length appropriate light (460-480 nm light) causes a rapid drop in melatonin (23, 29). Given that the regular circadian production of pineal melatonin is a reflection of the activity of the SCN, then it is obvious that light during the normal dark period imposes a marked misalignment of the central circadian pacemaker and the peripheral cellular clocks. This creates a situation that surely must lead to malfunctions at the cellular and tissue levels (76-79). Certainly, chronodisruption in terms of the potential negative consequences it has for optimal health has attracted a great deal of investigative interest within the last decade. It seems likely that disease states as diverse of metabolic syndrome and psychological depression may be consequences of circadian misalignment (80-83).

One particular disease that has frequently been discussed relative to excessive or abnormal light exposure is cancer (51, 84-




Fig. 2. In addition of pineal melatonin released on circadian manner, about 500 times of this indoleamine is generated and released by the EE cells of the gastrointestinal tract (GIT) to serve as local protector of the GIT mucosa and the liver (Adapted with permission from ref. 89).

87). There is a vast amount of literature suggesting that the photoperiodic environment influences the incidence of cancer. While an association of chronodisruption was initially proposed only for breast cancer, we recently suggested a more general theory, *i.e.*, chronodisruption may aggravate the development of many cancer types (52). Melatonin demonstrates dose-dependent inhibition on the growth of MCF-7 breast cancer cells. In fact, the International Agency for Research on Cancer has classified light at night as a Group 2A carcinogen, *i.e.*, a probable carcinogen in humans (51). The elevated cancer incidence that is believed to be a result of light exposure at night could be a consequence of, i), a depression in melatonin, ii), chronodisruption or, iii), both of these. Certainly, many scientific publications have documented that melatonin is oncostatic and, likewise, perturbations of circadian rhythmicity also lead to accelerated tumor growth (51, 81, 82).

Melatonin also plays an important role in regulation (partly *via* the brain gut axis) and in direct protection of the mucosa of gastrointestinal tract (GIT) being generated and released by the EE cells of the GIT in enormous amounts to portal circulation to protect the liver and biliary tract from various irritants.

It has repeatedly been found to provide gastroprotective effects against ethanol, cold-stress, aspirin, and ischemia-reperfusion induced gastric lesions (86, 87). A three-month human trial has revealed that oral administration of melatonin, combined with modification of diet and exercise, decreased plasma liver enzyme levels in NASH (nonalcoholic steatohepatitis) patients greater than diet and exercise alone (88). Another recent human trial has found that administration of exogenous melatonin was successful in attenuating proinflammatory cytokine levels (89) (Fig. 2).

CONCLUDING REMARKS

A large number of scientists seem to have come to the realization that light exposure at inappropriate times, *i.e.*, at night, may not be as innocuous as assumed. Again, the reader is reminded that throughout evolution all animals including humans were exposed to regularly repeating periods of light and darkness. This cycle induced the evolution of a master clock in the brain so as to use that information for the physiological well being of the

organism. With the invention of the light bulb by Thomas Alva Edison in 1879, the lighting environment in which we live changed drastically. What is now best described as light pollution has significantly impacted both physiology and behavior. Leisure activities and work schedules have spread throughout the 24 hours. This has led to severe disruptions of circadian rhythms at both the cellular and organismal levels. Likewise, the quantity of melatonin produced on a daily basis has been substantially depleted. Such perturbations are likewise not physiologically trivial and to consider these perturbations to be insignificant would seemingly be naive considering what we currently know about the significance of circadian rhythmicity and of the importance of melatonin.

Circadian rhythmicity is an integral component of normal and optimal physiology. Not only the SCN, but cells throughout the organism are equipped with internal clocks that control the molecular events that occur during each 24-hour period. These events appear to be precisely timed and in modern societies the intrinsic time keepers are provided with misinformation which, when prolonged, likely has ramifications in terms of increased pathologies. It would seem judicious to take better care of the circadian network by providing appropriate photoperiodic cues, which currently seemed to be almost totally ignored. In addition, large amounts of this indoleamine is produced in the mucosa of GIT that seems to serve as local antioxidant and protective substance for the gut and liver against a variety of noxious agents, particularly the bacteria and their toxins, introduced into the gut with each meal.

Acknowledgements: A preliminary report of this work was presented at the International Symposium on Biological Clocks: Pathophysiology and Clinical Aspects, Cracow, Poland, June 25th, 2010.

Conflicts of interest: None declared.

REFERENCES

- Mazzoccoli G. The timing clockwork of life. *J Biol Regul Homeost Agents* 2011; 25: 137-143.
- Karatsoreos IN, Bhagat S, Bloss EB, Morrison JH. Disruption of circadian clocks has ramifications for metabolism, brain, and behavior. *Proc Natl Acad Sci USA* 2011; 108: 1657-1662.
- Schwartz WJ. Circadian rhythms: a tale of two nuclei. *Curr Biol* 2009; 19: R460-R462.
- Welsh DK, Takahashi JS, Kay SA. Suprachiasmatic nucleus: cell autonomy and network properties. *Annu Rev Physiol* 2010; 72: 551-577.
- Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery in health and disease. *Nat Rev Neurosci* 2003; 4: 649-661.
- Erren TC, Reiter RJ. Defining chronodisruption. *J Pineal Res* 2009; 46: 245-247.
- Green CB, Takahashi J, Bass J. The meter of metabolism. *Cell* 2008; 134: 728-742.
- Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system. *Annu Rev Physiol* 2010; 72: 517-549.
- Sack RL, Lewy AJ, Keith LD, Nakagawa H. Circadian rhythm abnormalities in totally blind people: incidence and clinical significance. *J Clin Endocrinol Metab* 1992; 75: 127-134.
- Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. *N Eng J Med* 2000; 343: 1070-1077.
- Barnard AR, Nolan PM. When clocks go bad: neurobehavioral consequences of disrupted circadian timing. *PLoS Genet* 2008; 4:e1000040.

12. Rüger M, Scheer FA. Effects of circadian disruption on the cardiometabolic system. *Rev Endocr Metab Disord* 2009; 10: 245-260.
13. Erren TC, Pape HC, Reiter RJ, Piekarski C. Chronodisruption and cancer. *Naturwissenschaften* 2008; 95: 357-382.
14. Kohsaka A, Bass J. A sense of time: how molecular clocks organize metabolism. *Trends Endocr Metab* 2007; 18: 4-11.
15. Challet E. Entrainment of the suprachiasmatic clockwork in diurnal and nocturnal mammals. *Endocrinology* 2007; 148: 5648-5655.
16. Wright HR, Lack LC. Effect of light wavelength on suppression and phase delay of the melatonin rhythm. *Chronobiol Int* 2001; 18: 801-808.
17. Schmidt TM, Kofuji P. Structure and function of bistratified intrinsically photosensitive retinal ganglion cells in the mouse. *J Comp Neurol* 2011; 519: 1492-1504.
18. Do MT, Yau KW. Intrinsically photosensitive retinal ganglion cells. *Physiol Rev* 2010; 90: 1547-1581.
19. Ecker JL, Dumitrescu ON, Wong KY, et al. Melanopsin-expressing retinal ganglion-cell photoreceptors: cellular diversity and role in pattern vision. *Neuron* 2010; 67: 49-60.
20. Davies WL, Foster RG, Hankins MW. Focus on molecules: melanopsin. *Exp Eye Res* 2010; Aug 7: (pub ahead of print).
21. Hankins MW, Peirson SN, Foster RG. Melanopsin: an exciting photopigment. *Trends Neurosci* 2008; 31: 27-36.
22. Vandewalle G, Schmidt C, Albouy G, et al. Brain responses to violet, blue and green monochromatic light exposures in humans: prominent role of blue light and the brain stem. *PLoS One* 2007; 2: e1247.
23. Kawasaki A, Kardon RH. Intrinsically photosensitive retinal ganglion cells. *J Neuroophthalmol* 2007; 27: 195-204.
24. Canteros NS, Ribeiro-Barbosa ER, Goto M, Cipolla-Neto J, Swanson LW. The retinohypothalamic tract: comparison of axonal projection patterns from four major targets. *Brain Res Rev* 2011; 65: 150-183.
25. Morin LP, Shivers KY, Blanchard JH, Muscat L. Complex organization of mouse and rat suprachiasmatic nucleus. *Neuroscience* 2006; 137: 1285-1297.
26. Moore RY, Speh JC. Serotonin innervation of the primate suprachiasmatic nucleus. *Brain Res* 2004; 1010: 169-173.
27. Grone BP, Chang D, Bourgin P, et al. Acute light exposure suppresses circadian rhythms in clock gene expression. *J Biol Rhythms* 2011; 26: 78-81.
28. Maywood ES, O'Neill JS, Reddy AB, et al. Genetic and molecular analysis of the central and peripheral circadian clockwork of mice. *Cold Spring Harb Symp Quant Biol* 2007; 78: 85-94.
29. Asher G, Gatfield D, Stratmann M, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. *Cell* 2008; 134: 317-328.
30. O'Neill JS, Maywood ES, Chesham JE, Takahashi JS, Hastings MH. cAMP-dependent signaling as a core component of the mammalian circadian pacemaker. *Science* 2008; 320: 949-953.
31. Maywood ES, Chesham JE, Meng QJ, Nolan PM, Loudon AS, Hastings MH. Tuning of the period of the mammalian circadian clock: additive and independent effects of CK, 1 α Tau, and Fbx13Afh mutations on mouse circadian behavior and molecular pacemaking. *J Neurosci* 2011; 31: 1539-1544.
32. Ptitsyn AA, Zvonc S, Conrad SA, Scott LK, Mynatt RL, Gimble JM. Circadian clocks are resounding in peripheral tissues. *PLoS Comput Sci* 2006; 2: e16.
33. Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. *Annu Rev Physiol* 2010; 72: 517-549.
34. Gerstner JR. The aging clock: 'BMAL'icious toward learning and memory. *Aging* 2010; 2: 251-254.
35. Farnell YF, Shende VR, Neuendorff N, Allen GC, Earnest DJ. Immortalized cell lines for real-time analysis of circadian pacemaker and peripheral oscillator properties. *Eur J Neurosci* 2011; 33: 1533-1540.
36. Klerman EB, Duffy JF, Dijk DJ, Czeisler CA. Circadian phase resetting in older people by ocular bright light exposure. *J Invest Med* 2001; 49: 30-40.
37. Hanifin JP, Brainard GC. Photoreception for circadian, neuroendocrine and neurobehavioral regulation. *J Physiol Anthropol* 2007; 26: 87-94.
38. Smale L, Cassone VM, Moore RY, Morin LP. Paraventricular nucleus projects mediating pineal melatonin and gonadal responses to photoperiod in the hamster. *Brain Res Bull* 1989; 22: 263-269.
39. Moore RY. Neural control of pineal function in mammals and birds. *J Neural Transm* 1978(Suppl): 47-58.
40. Karasek M. Ultrastructure of the mammalian pineal gland: its comparative and functional aspects. *Pineal Res Rev* 1983; 1: 1-48.
41. King TS, Steinlechner S. Pineal indolalkylamine synthesis and metabolism: kinetic considerations. *Pineal Res Rev* 1985; 3: 69-114.
42. Maronde E, Saade A, Ackermann K, et al. Dynamics in enzymatic protein complexes offer a novel principle for the regulation of melatonin synthesis in the human pineal gland. *J Pineal Res* 2011; 51: 145-155.
43. Vaughan GM, Pelham RW, Pang SF, et al. Nocturnal elevation of plasma melatonin and urinary 5-hydroxyindoleacetic acid in young men: attempts at modification by brief changes in environmental lighting and sleep and by autonomic drugs. *J Clin Endocrinol Metab* 1976; 42: 752-764.
44. Tricoire H, Locatelli A, Chemineau P, Malpoux B. Melatonin enters the cerebrospinal fluid through the pineal recess. *Endocrinology* 2002; 143: 84-90.
45. Tan DX, Manchester LC, Sanchez-Barcelo E, Mediavilla MD, Reiter RJ. Significance of high levels of endogenous melatonin in mammalian cerebrospinal fluid and in the central nervous system. *Curr Neuropharmacol* 2010; 8: 162-167.
46. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. *Endocr Rev* 1991; 12: 151-180.
47. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. *Science* 1980; 210: 1267-1269.
48. Stevens RG, Blask DE, Brainard GC, et al. Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. *Environ Health Perspect* 2007; 115: 1357-1362.
49. Erren TC, Reiter RJ. A generalized theory of carcinogenesis due to chronodisruption. *Neuroendocrinol Lett* 2008; 29: 815-821.
50. Filipinski E, Levi F. Circadian disruption in experimental cancer processes. *Integr Cancer Ther* 2009; 8: 299-302.
51. Reiter RJ, Tan DX, Sanchez-Barcelo E, Mediavilla MD, Gitto E, Korkmaz A. Circadian mechanisms in the regulation of melatonin synthesis: disruption with light at night and the pathophysiological consequences. *J Exp Integr Med* 2011; 1: 13-22.
52. Wehr TA. The duration of human melatonin secretion and sleep respond to changes in daylength (photoperiod). *J Clin Endocrinol Metab* 1991; 73: 1276-1280.
53. Gallup Organization. Sleep in America. Princeton, WJ, Gallup Organization, 1995.
54. Kripke D, Simons R, Garfinkel L, Hammond E. Short and long sleep and sleeping pills: is increased mortality associated? *Arch Gen Psychiatr* 1979; 36: 103-116.

55. National Center for Health Statistics. Quick stats: percentage of adults who report an average of 6 hours of sleep per 24 hour period by sex and age group - United States, 1985-2004. *Biol Psychiatry* 2000; 47: 921-927.
56. Van Cauter E, Spiegel K, Tasali E, Leproult R. Metabolic consequences of sleep and sleep loss. *Sleep Med* 2008; 9(Suppl 1): S23-S28.
57. Reiter RJ. Melatonin: that ubiquitously-acting pineal hormone. *Neurophysiol Sci* 1990; 6: 223-227.
58. Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: a multitasking molecule. *Prog Brain Res* 2010; 181: 127-151.
59. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. *Endocr J* 1993; 1: 57-60.
60. Paradies G, Petrosillo G, Paradies V, Reiter RJ, Ruggiero FM. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. *J Pineal Res* 2010; 48: 297-310.
61. Jou MJ, Peng TI, Hsu LF, et al. Visualization of melatonin's multiple mitochondrial levels of protection against mitochondrial Ca²⁺ mediated permeability transition and beyond in rat brain astrocytes. *J Pineal Res* 2010; 48: 20-38.
62. Mukherjee D, Roy SC, Bandyopadhyay A, et al. Melatonin protects against isoproterenol-induced myocardial injury in the rat: antioxidative mechanisms. *J Pineal Res* 2010; 48: 251-262.
63. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. *Crit Rev Biochem Mol Biol* 2009; 44: 175-200.
64. Acuna-Castroviejo D, Lopez LC, Escames G, Lopez A, Garcia JA, Reiter RJ. Melatonin-mitochondria interplay in health and disease. *Curr Top Med Chem* 2011; 11: 221-240.
65. Reiter RJ, Richardson BA, Johnson LY, Ferguson BN, Dinh DT. Pineal melatonin rhythm: reduction in aging Syrian hamsters. *Science* 1980; 210: 1372-1373.
66. Reiter RJ, Craft CM, Johnson LY, et al. Age-associated reduction in nocturnal pineal melatonin levels in female rats. *Endocrinology* 1981; 109: 1295-1297.
67. Sack RL, Lewy AJ, Erb DL, Vollmer WM, Singer CM. Human melatonin production decreases with age. *J Pineal Res* 1986; 3: 379-388.
68. Harman D. Aging: overview. *Ann NY Acad Sci* 2001; 928: 1-21.
69. Chahbouni M, Escames G, Venegas C, et al. Melatonin treatment normalized plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. *J Pineal Res* 2010; 48: 282-290.
70. Akbulut KG, Gonul B, Akbulut H. Exogenous melatonin decreases age-induced lipid peroxidation in the brain. *Brain Res* 2008; 1238: 31-35.
71. Molpeceres V, Mauriz JL, Garcia-Mediavilla MV, Gonzalez P, Barrio JP, Gonzalez-Gallego J. Melatonin is able to reduce the apoptotic liver changes induced by aging via inhibition of the intrinsic pathway of apoptosis. *J Gerontol A Biol Sci Med Sci* 2007; 62: 687-695.
72. Cardinali DP, Furio AM, Brusco JL. Clinical aspects of melatonin intervention in Alzheimer's disease progression. *Curr Neuropharmacol* 2010; 8: 218-227.
73. Turek FW, Joshu C, Kohsaka A, et al. Obesity and metabolic syndrome in circadian Clock mutant mice. *Science* 2005; 308: 1043-1045.
74. Garaulet M, Madrid JA. Chronobiology, genetic and metabolic syndrome. *Curr Opin Lipidol* 2009; 20: 127-134.
75. Reiter RJ, Tan DX, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact in hypertension. *J Hypertens (Suppl)* 2009; 27: S17-S20.
76. Reiter RJ, Tan DX, Korkmaz A, Ma S. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation and melatonin suppression. *Ann Med* 2011; Jun 13: (epub ahead of print).
77. Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez JJ, Kaski JC, Reiter RJ. Melatonin and circadian biology in human cardiovascular disease. *J Pineal Res* 2010; 49: 14-22.
78. Jung-Hynes B, Reiter RJ, Ahmad N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. *J Pineal Res* 2010; 48: 9-19.
79. Bubenik GA, Konturek SJ. Melatonin and aging: prospects for human treatment. *J Physiol Pharmacol* 2011; 62: 13-19.
80. Bron R, Furness JB. The rhythm of digestion: keeping time in the gastrointestinal tract. *Clin Exp Pharmacol Physiol* 2009; 36: 1041-1048.
81. Reiter RJ, Tan DX, Korkmaz A, et al. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. *Crit Rev Oncogen* 2007; 13: 303-328.
82. Blask DE. Melatonin, sleep disturbances and cancer risk. *Sleep Med Rev* 2009; 13: 357-364.
83. Hill SM, Frasca T, Xiang S, Yuan L, Duplessis T, Mao L. Molecular mechanisms of melatonin anticancer effects. *Integr Cancer Ther* 2009; 8: 337-346.
84. Wood PA, Yang X, Hrushesky WJ. Clock genes and cancer. *Integr Cancer Ther* 2009; 8: 301-308.
85. Reiter RJ, Tan DX, Erren TC, Fuentes-Broto L, Paredes SD. Light-mediated perturbations of circadian timing and cancer risk: a mechanistic analysis. *Integr Cancer Ther* 2009; 8: 354-360.
86. Brzozowski I, Ptak-Belowska A, Pawlik M, et al. Mucosal strengthening activity of central and peripheral melatonin in the mechanism of gastric defense. *J Physiol Pharmacol* 2009; 60: 47-56.
87. Konturek PC, Celinski K, Slomka M, et al. Melatonin and its precursor L-tryptophan prevent acute gastric mucosal damage induced by aspirin in humans. *J Physiol Pharmacol* 2008; 59(Suppl 2): 67-75.
88. Gonciarz M, Gonciarz Z, Bielanski W, et al. The pilot study of a 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: Effect on plasma levels of liver enzymes, lipids and melatonin. *J Physiol Pharmacol* 2010; 61: 705-710.
89. Konturek SJ, Konturek PC, Brzozowski T, Bubenik GA. Role of melatonin in the upper gastrointestinal tract. *J Physiol Pharmacol* 2008; 58(Suppl 6): 23-52.

Received: February 15, 2011

Accepted: June 27, 2011

Author's address: Prof. Russel J. Reiter, Department of Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, Texas, USA 78229; E-mail: reiter@uthscsa.edu